Nearly three years after the FDA convened experts for a public workshop to address the unmet need for antifungal agents, the antifungal pipeline remains small due to a host of hurdles.
Infectious Disease Special Edition spoke with several experts who presented at the FDA workshop to see where progress has—and has not—been made in addressing the dearth of effective antifungal agents.
“Although numbers of serious fungal infections are increasing slightly, the main